

Supplementary Table 1. Laboratory test results for AST, ALT, and hs-CRP

Characteristic	Evolocumab group (n = 50)	Non-evolocumab group (n = 45)	p value
Baseline			
AST (50/45)	37.0 (27.2–64.2)	37.0 (27.0–46.0)	0.240
ALT (50/45)	28.5 (20.0–41.0)	24.0 (14.0–32.0)	0.030
AST/ALT abnormality ^{a)}	29 (58.0)	22 (48.9)	0.415
AST/ALT > 3 times the upper limit of the normal range	5 (10.0)	3 (6.7)	0.718
Hs-CRP, mg/L (48/43)	1.3 (0.7–4.0)	1.8 (0.6–8.4)	0.575
1–3 weeks lowest value			
AST (36/43)	25.5 (19.0–29.0)	25.0 (20.0–31.0)	0.756
ALT (36/43)	31.0 (22.0–48.2)	22.0 (15.0–31.0)	0.019
AST/ALT > 3 times the upper limit of the normal range	1 (2.8)	0 (0.0)	0.456
Hs-CRP, mg/L (26/34)	1.6 (0.7–5.5)	2.2 (0.9–8.8)	0.368
3–8 weeks lowest value			
AST (45/44)	27.0 (21.2–33.5)	24.5 (18.8–30.5)	0.187
ALT (45/44)	34.0 (25.0–41.8)	26.5 (17.8–35.5)	0.058
AST/ALT > 3 times the upper limit of the normal range	2 (4.0)	0 (0.0)	0.497
Hs-CRP, mg/L (41/37)	0.7 (0.6–1.3)	0.9 (0.6–3.7)	0.408

Values are presented as median (interquartile range) or number (%).

AST, aspartate aminotransferase; ALT, alanine aminotransferase; Hs-CRP, high-sensitivity C-reactive protein.

^{a)}AST/ALT abnormality is defined as AST or ALT level more than 40 IU/L.